Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alison Handley, Eric Lloyd, Andrew Roberts & Bruce Barger. (2016) Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clinical and Experimental Hypertension 38:2, pages 180-188.
Read now
Read now
Vivencio Barrios & Carlos Escobar. (2013)
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?. Expert Opinion on Pharmacotherapy 14:16, pages 2249-2261.
Read now
Read now
Carlos Escobar & Vivencio Barrios. (2013) An evaluation of the latest evidence relating to renin–angiotensin system inhibitors. Expert Opinion on Drug Metabolism & Toxicology 9:7, pages 847-858.
Read now
Read now
Amedeo Mugellini & Valentina Nieswandt. (2012) Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opinion on Pharmacotherapy 13:18, pages 2699-2709.
Read now
Read now
Articles from other publishers (5)
Ami Kwon & Gee-Hee Kim. (2020) Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review. Clinical Therapeutics 42:7, pages 1390-1403.
Crossref
Crossref
Joel M. Neutel, William C. Cushman, Eric Lloyd, Bruce Barger & Alison Handley. (2017) Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. The Journal of Clinical Hypertension 19:9, pages 874-883.
Crossref
Crossref
Ruhul Kayesh, Md. Sarowar Jahan & Md. Zakir Sultan. (2017) Development Using Response Surface Methodology and Validation of a Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Azilsartan Medoxomil and Chlorthalidone in Solid Dosage Form. Chromatographia 80:4, pages 593-603.
Crossref
Crossref
M. G Bubnova. (2015) Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part II. CardioSomatics 6:3, pages 58-69.
Crossref
Crossref
Mark S. Kipnes, Alison Handley, Eric Lloyd, Bruce Barger & Andrew Roberts. (2015) Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension. The Journal of Clinical Hypertension 17:3, pages 183-192.
Crossref
Crossref